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Heart failureWehave demonstratedusing immunoprecipitation and immunostaining a novel physical association of the P2X4
receptor (P2X4R), a ligand-gated ion channel, with the cardioprotective, calcium-dependent enzyme endothelial
nitric oxide synthase (eNOS). Treatment ofmurine ventricularmyocyteswith the P2XR agonist 2-methylthioATP
(2-meSATP) to induce a current (mainly Na+) increased the formation of nitric oxide (NO), as measured using a
ﬂuorescent probe. Possible candidates for downstream effectors mediating eNOS activity include cyclic GMP and
PKG or cellular protein nitrosylation. A cardiac-speciﬁc P2X4R overexpressing mouse line was protected from
heart failure (HF) with improved cardiac function and survival in post-infarct, pressure overload, and
calsequestrin (CSQ) overexpression models of HF. Although the role of the P2X4R in other tissues such as the
endothelium and monocytes awaits characterization in tissue-speciﬁc KO, cardiac-speciﬁc activation of eNOS
may be more cardioprotective than an increased activity of global systemic eNOS. The intra-myocyte formation
of NO may be more advantageous over NO derived externally from a donor. A small molecule drug stimulating
this sarcolemmal pathway or gene therapy-mediated overexpression of the P2X4R in cardiac myocytes may
represent a new therapy for both ischemic and pressure overloaded HF.
© 2014 Yang et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural
Biotechnology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2. Identiﬁcation and characterization of cardiac myocyte P2X4 receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
3. Regulation of P2X receptors in diseased hearts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
4. P2X4R associates with eNOS and can induce NO formation with downstream signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
5. Role of eNOS in mediating the protective effect of P2X4R in HF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
6. Protective role of endogenous cardiac myocyte P2X4R in heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
7. Summary and outlook. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
8. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
8.1. Mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
8.2. Isolation and Measurement of NO Production in Adult Mouse Cardiac Ventricular Myocytes . . . . . . . . . . . . . . . . . . . . . . . . 6
8.3. Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6University of ConnecticutMedical Center, 263 Farmington Ave., MC3946, Farmington, CT 06032, United States. Tel.: +1 860 679
n behalf of the Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY
2 R. Yang et al. / Computational and Structural Biotechnology Journal 13 (2015) 1–71. Introduction
Since the original proposal of purinergic transmission by Burnstock
[1], the ﬁeld of purinergic receptors and signaling has grown exponen-
tially. Extracellular ATP and adenosine activating their P2 and P1
purinergic receptors, respectively, mediate a growing number of biolog-
ical functions. Adenosine (P1) and P2Y12 receptors have already become
targets for cardiovascular disease [2,3]. P2X receptors (P2XRs) are
trimeric ion channels with a molecular weight of each monomer of
43,438 Da (mouse) or 43,369 Da (human). This receptor channel is ac-
tivated by ATP and its analogues. The subunit composition of a given
P2X channel may be homotrimeric, i.e. of the same P2XR protein, or
heterotrimeric, which is known to affect the ligand pharmacology. In
the current review, we summarized a novel feature of the P2X4R in
that the receptor is not just an ion channel, but it also physically associ-
ates with the enzyme endothelial nitric oxide synthase (eNOS). In the
cardiac myocyte, we show that P2X4R stimulation causes activation of
eNOS, as demonstrated by increased nitric oxide (NO) formation, with
two structurally different NO-sensitive ﬂuorescent dyes. Functionally,
the P2X4R–eNOS pathway is important in mediating cardioprotection
in heart failure (HF).
2. Identiﬁcation and characterization of cardiac myocyte
P2X4 receptors
Adult ventricular myocytes from mice, rat and guinea pig show an
inward current in response to extracellular ATP [3]. ATP elicited anFig. 1. P2X4Rand eNOSphysically associatewith each other as evidenced by co-immunoprecipit
myocyte lysateswere incubatedwith anti-eNOS antibody orwith non-speciﬁc IgG as control. Th
usingwestern blotting. In a control experiment, eNOS co-immunoprecipitated itself. Co-immun
shown. (b) Same experiment as in (a) conducted in P2X4-Tgmyocytes. (c) Immunostaining of
cardiac myocyte.
The ﬁgure and its legend are reproduced with permission fromWolters Kluwer Health (see Acincrease in a non-selective cation current with a reversal potential
near 0 mV, which is similar to that of cloned P2X4Rs [4]. In murine
ventricular myocytes, the current induced by the P2XR agonist
2-methylthioATP (2-meSATP) is partially insensitive to antagonism by
suramin and pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid
(PPADS),which is also characteristic of the P2X4R [4]. As an ion channel,
the P2X4R conducts current carried by both Na+ and Ca2+. Although
the P2X4R is a calcium permeant channel, the majority of the inward
current is carried by Na+. Initially, it was predicted that this channel
would be deleterious in the heart because of the potential calcium over-
load caused by the inﬂux of Na+ and Ca2+. Under basal control condi-
tions, mice with cardiac-speciﬁc P2X4R overexpression were overtly
normal without cardiac hypertrophy or failure as they age [5]. Paradox-
ically, thesemice are protected fromHFwith improved cardiac function
and survival with post-infarct, pressure overload, and calsequestrin
(CSQ) overexpression-induced HF [6–8].
3. Regulation of P2X receptors in diseased hearts
A question arises as to whether cardiac P2X receptors are regulated
during pathological conditions. For example, are these receptors up- or
down-regulated in disease states such as heart failure? As we gain
understanding of the role of cardiac P2X receptors, their regulation in
diseased hearts may have implications for the progression of the dis-
ease. In our previous study, the expression of the cardiac P2X4 receptor
is increased in the CSQ mice-overexpressing model of hypertrophy and
dilated cardiomyopathy. The P2X agonist-stimulated current is alsoation and co-localization in cardiac ventricularmyocytes ofWTand P2X4RTgmice. (a)WT
e isolated complexwas probedwith eNOS (toppanel) and P2X4 (bottompanel) antibodies
oprecipitation of P2X4Rwith eNOS antibody (lane 3) but notwith control IgG (lane 2)was
eNOS (green), P2X4R (red), andmerged image was shown for a P2X4R-overexpressing Tg
knowledgment).
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WTmice [8], consistentwith a potential pathophysiological signiﬁcance
of the cardiac P2X4 receptor. In another study by Musa et al. [9], P2X4
mRNAwas up-regulated in the sinoatrial node in rats with coronary ar-
tery ligation-induced heart failure, with a trend toward an increased
P2X4 receptor expression in the left ventricle and right atrium as well.
P2X4 receptor expression was also shown to be up-regulated in right
ventricles of rats exposed to hypoxia [10]. In post-infarct WT hearts,
the P2X4 receptor expression is not changed in the remote non-
infarcted region as assessed by immunoblotting (unpublished observa-
tion). Studies on human hearts also suggest that all of the P2X subtypes
are detectable in the myocardium [11], with P2X4 receptors expressed
in failing hearts at the same level as in healthy donor hearts.4. P2X4R associates with eNOS and can induce NO formation with
downstream signaling
Since the P2X4R is calcium permeant, it is possible that this receptor
can interact with and activate the calcium-dependent endothelial nitric
oxide synthase (eNOS). Data summarized in Fig. 1 show that P2X4R is
co-localized with eNOS in the sarcolemma (Fig. 1c) and is present in
eNOS immunoprecipitates obtained from cardiac myocytes of both
WT (Fig. 1a) and P2X4R Tg (Fig. 1b) hearts. The speciﬁcity of this
physical interaction is supported by the absence of P2X4R in
immunocomplexes captured using an IgG matched control antibody.Fig. 2. P2X agonist 2-meSATP stimulated cardiac myocyte NO formation in P2X4R Tg and WT
overexpressing Tg cardiac ventricular myocytes before and after SNAP or 2-meSATP treatment a
in arbitrary units (A.U.) before and after treatmentwith SNAP (4=mice) or 2-meSATP (n=3m
myocytes fromWT animals (n=3mice). Upper and lower panels show typical ﬂuorescence im
t-test for averageﬂuorescence intensity in arbitrary units (A.U.) before and after treatmentwith
were counted.In the immunostaining, the two proteins co-localized over a speciﬁc
region in the myocyte, as demonstrated by plotting staining over
distance (Fig. 1c inset with the line plot). Both proteins co-localized in
the merged staining. Both proteins also showed sarcolemmal staining
and co-localization in WT myocytes, although P2X4R staining was
considerably fainter [12], likely reﬂecting the low level of endogenous
receptor expression. Despite this, we observed the co-localization of
P2X4R with eNOS at the sarcolemma of WT cardiac myocytes.
We next investigated whether this physical association of P2X4R
with eNOS can lead to formation of molecules downstream of eNOS fol-
lowing stimulation of cardiac P2X receptors. Previous results, using the
more traditional 4-amino-5-methylamino-2′,7′-diﬂuoroﬂuorescein
(DAF-FM) diacetate dye for imaging nitric oxide (NO) in P2X4R Tg
cardiac myocytes, showed enhanced ﬂuorescence over the baseline or
vehicle-treated ﬂuorescence following 2-meSATP treatment [12]. DAF-
FM has the drawback of ﬂuorescence bleaching. Here we report new
data with a novel NO-sensitive ﬂuorescent dye, 2-{4,5-bis[(6-(2-
ethoxy-2-oxoethoxy)-2-methylquinolin-8-ylamino)methyl]-6-hydoxy-
3-oxo-3H-xanthen-9-yl}benzoic acid (FL2E) in its copper complex
form (Cu2(FL2E)), to image NO formation in biological systems
including intact living cardiac myocytes [13–15]. Our new data, sum-
marized in Fig. 2, conﬁrmed NO formation following 2-meSATP stim-
ulation in the P2X4R Tg myocytes. To determine the physiological
relevance of the P2X4–eNOS coupling, we found that WT myocytes
also exhibit increased NO formation after 2-meSATP stimulation
(Fig. 2b). These data directly demonstrated, using a novel NO-animals. Upper panel: Representative ﬂuorescence images of Cu2(FL2E) loaded P2X4R-
re shown (a). Lower ﬁgure: *P b 0.05 using paired t-test for average ﬂuorescence intensity
ice) from P2X4R Tg animals (a). (b) Similar studieswere carried out in cardiac ventricular
aging and average A.U. for treatmentwith SNAP andwith 2-meSATP. *P b 0.05 using paired
SNAPor 2-meSATP. Inmyocytes isolated fromeachmouse ofWTor Tg animals, 20–80 cells
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myocytes as a result of P2XR stimulation in not only the P2X4R-
overexpressing Tg myocytes but also the WT cardiac myocytes.
Thus, using two structurally different dyes speciﬁc for NO, we have
shown an increased NO level in cardiac myocytes as a result of
P2X4R stimulation. NO could cause further downstream activity,
most typically stimulation of soluble guanylyl cyclase activation
and 3′,5′-cyclic GMP (cGMP) formation, as well as the more recently
discovered S-nitrosylation of cellular proteins. Data summarized in
Fig. 3 showed that indeed there is an increased level of myocardial
S-nitrosylation in the P2X4R Tg hearts compared to WT hearts. The
cGMP level is also higher in Tg hearts than in WT hearts, consistent
with stimulation of the overexpressed cardiac P2X4R by endogenous
extracellular ATP leading to cGMP formation in the Tg hearts [12].
The increased eNOS activity in the P2X4R Tg heart was not due to
an up-regulation of eNOS because eNOS protein levels did not
change in Tg [12]. Overall, multiple lines of evidence point to a
P2X4R-induced intra-myocyte NO production with downstream
functional consequences.
5. Role of eNOS in mediating the protective effect of P2X4R in HF
Having established activation of eNOS by P2X4R, we next studied
the function of eNOS as a mediator of P2X4R protection. We used aFig. 3. Increased cardiac protein S-nitrosylation levels in P2X4R Tg animals. A typical ex-
ample of S-nitrosylated proteins in P2X4R-overexpressing Tg and WT hearts (n = 5 for
each) is shown as determined using biotin switch method. The counts of total summed
intensities produced one distribution for each heart and analyzed with Kolmogorov–
Smirnov test for equality of distributions. The test is rejected (P b 0.001) in favor of the
distributions not being the same.
The ﬁgure and its legend are reproduced with permission fromWolters Kluwer Health
(see Acknowledgment).
Fig. 4. P2X4R KO mice showed a more severe HF phenotype after infarction. WT and KO
mice were subjected to sham operation or LAD ligation and cardiac functions determined
ninety days later. KO hearts had a lower+dP/dt (a), by ex vivoworking heart preparation
(n= 39) as well as a more reduced FS by in vivo echocardiography (b, n = 20) than WT
hearts (n = 19 and 11 for ex and in vivo measurements respectively). Both WT and KO
hearts showed lower +dP/dt and FS than either sham WT (n = 10 for +dP/dt, n = 6
for FS) or sham KO (n = 19 for +dP/dt, n = 9 for FS) hearts. *P b 0.05 for ligated WT
vs. shamWT, sham KO or ligated KO. **P b 0.05 for ligated KO vs. shamWT or sham KO.
P N 0.05 for shamWT vs. sham KO.
The ﬁgure and its legend are reproduced with permission from Wolters Kluwer Health
(see Acknowledgment).pharmacological inhibitor of eNOS, L-N5-(1-iminoethyl)ornithine hy-
drochloride (L-NIO), and gene ablation of eNOS in P2X4R Tgmice during
HF. Cardiac transgenic (Tg) P2X4R overexpression caused a higher car-
diac left ventricular fractional shortening (FS) after infarction in the
P2X4 Tg mice than non-transgenic WT animals. In these studies, per-
manent coronary ligation caused post-infarct HF but did not inﬂuence
the infarct size in mice of various genotypes that are subjected to the
ligation. Permanent coronary ligation represents a commonly used
ischemic HF model. Daily injection with L-NIO—used to demonstrate
eNOS function in vivo [16]—abrogated the improved cardiac perfor-
mance of P2X4R Tg mice during ischemic HF, as determined by
both in vivo echocardiography and in an ex vivo working heart
preparation.
In further conﬁrming the role of eNOS in mediating the protective
effect of the P2X4R during HF, eNOS KO mice were crossed with
P2X4R Tg mice (P2X4R Tg/eNOS KO). KO of eNOS abrogated the
protected phenotype conferred by the P2X4R Tg genotype in post-
infarction HF. Both the improved +dP/dt and FS in P2X4R Tg mice
during HF were lost in P2X4 Tg/eNOS KO mice. To ascertain whether
the protective effect of P2X4R–eNOS is applicable to another form of
HF, we tested the effects of P2X4R-induced protection by pharmacolog-
ical inhibition of eNOS on pressure overload HF. Pressure overload was
produced by aortic banding in P2X4R Tg andWTmice. P2X4R Tg hearts
Fig. 5. P2X4R KO hearts also had a more impaired function after TAC. WT and KO mice
were subjected to sham operation or TAC and cardiac functions determined seven days
later. KO mice showed a lower +dP/dt (a) by working heart (n = 10), as well as a
more reduced FS (b) and a larger left ventricular internal dimension at systole (LVIDs)
(c) by echocardiography (n = 9) than control WT mice (n = 5 for working hearts and
n = 13 for echocardiography). KO hearts showed lower +dP/dt, LVdevP and FS than
either sham WT (n = 10 for +dP/dt and LVdevP, n = 19 for FS) or sham KO (n = 9
for +dP/dt and LVdevP, n = 13 for FS) hearts. KO hearts also showed more dilated LVIDs
than shamWT or sham KO hearts. *P b 0.05 for banded KO vs. banded WT, shamWT or
sham KO; P N 0.05 for shamWT vs. KO; P N 0.05 for banded WT vs. shamWT or sham KO
in +dP/dt and LVIDs; P b 0.05 banded WT vs. shamWT or sham KO in FS comparison.
Theﬁgure and its legend are reproducedwith permission fromWolters Kluwer Health (see
Acknowledgment).
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derived FS after aortic banding. L-NIO blocked the increased FS in
these animals [12]. KO of eNOS in Tg animals also abrogated theimproved FS in these Tg mice after aortic banding. The data provided
functional evidence for a P2X4R–eNOS interaction and supported a
key role of eNOS as a mediator of cardiac P2X4R-induced protection in
HF.
6. Protective role of endogenous cardiac myocyte P2X4R in
heart failure
While studies in Tgmicewith cardiac P2X4R overexpression suggest
that cardiac P2X4R is important, thehigh level (N20 fold) of receptor ex-
pression makes these mice unsuitable to address the physiological role
of P2X4R. No direct evidence points to a role for the receptor in health or
disease. To study the heart function of the endogenous cardiac myocyte
P2X4R, we created a tamoxifen-responsive Cre-mediated knockout
(KO) of the P2X4R in cardiac myocytes.
Intact cardiac function of P2X4R KO animals was similar to WT
control (P2X4ﬂoxed/ﬂoxed/Myh6 negative) by echocardiography-derived
measures and byworking heart contractile parameters. KO cardiac ven-
tricular myocytes have the same resting cell length, width and contrac-
tion shortening as myocytes of WT littermates. KO hearts were similar
to control hearts without any evidence of ﬁbrosis or overt pathology.
Thus, cardiac speciﬁc P2X4R KO hearts have normal phenotypes with-
out hypertrophy,ﬁbrosis, or cardiac dysfunction at eithermyocyte or in-
tact heart levels. We then subjected the KO mice to left coronary artery
(LAD) ligation or pressure overload by transverse aorta constriction
(TAC) or aorta banding. The studies were designed to answer the ques-
tion on the function of endogenous cardiac myocyte P2X4R under basal
conditions or duringHF. KOhearts showed amore severe HF phenotype
after LAD ligation or aorta banding thanWT hearts. Cardiac FS by in vivo
echocardiography and +dP/dt by ex vivo working heart evaluation
showed impaired heart performance of KO mice in the post-infarct
heart failuremodel (Fig. 4). In the banded animals, KOmice also showed
a more decreased cardiac function than WT mice (Fig. 5), indicating a
general protective role of the endogenous myocyte receptor in animals
with HF caused by different etiologies.
7. Summary and outlook
P2X4Rs are ligand-gated ion channels and have emerged as poten-
tially important molecules in regulating cardiac function. The demon-
stration of a physical P2X4R–eNOS interaction is novel. Although eNOS
is cardioprotective, the downstream effectors mediating eNOS activity
are unknown (see Fig. 6 for model). Possible candidates include cyclic
GMP and PKG or cellular protein nitrosylation [3,17]. Our data also
have implications for the development of a P2X4R antagonist as a new
therapy to treat neuropathic pain [18]. Because the endogenous cardiac
myocyte P2X4R is cardioprotective, its antagonism during pain control
may be deleterious to those individuals under cardiac stress, including
HF. Although the role of the P2X4R in other tissues such as the endothe-
lium and monocytes awaits characterization in tissue-speciﬁc KO,
cardiac-speciﬁc activation of eNOS may be more cardioprotective than
an increased activity of global systemic eNOS [19]. The intra-myocyte
formation of nitric oxide may be more advantageous over nitric oxide
derived externally from a donor. A small molecule drug stimulating
this sarcolemmal pathway or gene therapy-mediated overexpression
of the P2X4R in cardiac myocytes may represent a new therapy for
both ischemic and pressure overloaded HF.
8. Methods
8.1. Mice
The UCHC Animal Care Committee, in compliance with Animal
Welfare Assurance, approved all mice handling procedures. P2X4R
overexpressing Tg mice were generated as previously described. WT
negative littermates and Tg mice were used at 10–12 weeks of age.
Fig. 6.Model of the mechanism of action of P2X receptors in cardiac myocytes. Stimulation of cardiac P2X4R activates eNOS. This is accomplished by a localized increase in calcium near
eNOS, binding to local calmodulin and leading to increased eNOS activity. A calcium gradient is set up by diffusion, with minor amounts reaching the SR. NO production can lead to stim-
ulation of two principal downstream effectors, soluble guanylyl cyclase with cyclic GMP accumulation and activation of protein kinase G (PKG) as well as S-nitrosylation of myocardial
proteins. These two downstream effectors represent both PKG-dependent and independent pathways, which are known to exert a salutary effect in heart failure and in ischemia/
reperfusion injury.
The ﬁgure is reproduced with permission fromWolters Kluwer Health (see Acknowledgment).
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Ventricular Myocytes
Ventricularmyocyteswere obtained fromP2X4RTg orWTmice as de-
scribed previously [4,5]. NO formation was measured by epiﬂuorescence
imaging of a new cell-trappable NO ﬂuorescent probe FL2E (Strem
Chemicals, Inc., Newburyport, MA). The Cu2(FL2E) NO dye was prepared
and stored according to manufacturer instructions. Before experiments,
myocyteswere loadedwith 5 μMCu2(FL2E)NOdye for 1 h in Tyrode's so-
lution, then plated onto glass bottom dishes for imaging with a Nikon
Eclipse TE2000-S. Fluorescence was captured with a 480/40 excitation
ﬁlter and 535/50 emission ﬁlter. Random 40× ﬁelds rich in rod shaped
striated myocytes were selected and recorded with a CCD camera.
Myocytes were incubated with buffer vehicle or 10 μM 2-meSATP
(Sigma), and ﬂuorescence was determined at baseline and after 10 min.
100 μM S-nitroso-N-acetyl-D,L-penicillamine (SNAP, Molecular Probes,
Life Technologies, Grand Island, NY) was used as a positive control treat-
ment. Fluorescence intensities from individual rod shapedmyocyteswere
quantiﬁed using ImageJ (NIH). Twenty to sixty myocytes were counted
from each plate before and after treatment for each mouse.
8.3. Statistics
Statistical differences were assessed by Student's t test. We consid-
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